Cycloheptyl-phenyl-glykolsaeure | 1620-01-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Cycloheptyl-phenyl-glykolsaeure
• 英文别名: Cycloheptylphenylglykolsaeure；2-Cycloheptyl-2-hydroxy-2-phenylacetic acid
• CAS: 1620-01-5
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: TZIJHUMOXVRAQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Cycloheptyl-phenyl-glykolsaeure 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、310.27 kPa 条件下， 反应 3.0h， 生成 (1α, 5α, 6α)-6-N-(3-azabicyclo [3.1.0] hexyl)-2-cycloheptyl-2-hydroxy-2-phenylacetamide
  参考文献：
  名称：

  Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists

  摘要：

  A series of constrained piperidine analogues were synthesized as novel muscarinic M-3 receptor antagonists. Evaluation of these compounds in binding assays revealed that they not only have high affinity for the M-3 receptor but also have high selectivity over the M-2 receptor. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.081
• 作为产物：
  描述：

  苯甲酰甲酸乙酯 在 氢氧化钾 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 Cycloheptyl-phenyl-glykolsaeure
  参考文献：
  名称：

  Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists

  摘要：

  A series of constrained piperidine analogues were synthesized as novel muscarinic M-3 receptor antagonists. Evaluation of these compounds in binding assays revealed that they not only have high affinity for the M-3 receptor but also have high selectivity over the M-2 receptor. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.081

文献信息

• [EN] 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'AZABICYCLO [3.1.0] HEXANE 3,6-DISUBSTITUES UTILISES COMME ANTAGONISTES DU RECEPTEUR MUSCARINIQUE
  申请人：RANBAXY LAB LTD

  公开号：WO2004052857A1

  公开（公告）日：2004-06-24

  The invention relates to derivatives of 3,6-disubstituted azabicyclo [3.1.0] hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

  这项发明涉及结构为(I)的3,6-二取代的氮杂双环[3.1.0]己烷衍生物。本发明的化合物可以作为肌碱受体拮抗剂，可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。该发明还涉及含有本发明化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。
• [EN] COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ ANTAGONISTE DES RÉCEPTEURS MUSCARINIQUES ET UNE ACTIVITÉ AGONISTE DES RÉCEPTEURS ADRÉNERGIQUE BÊTA-2
  申请人：CHIESI FARMA SPA

  公开号：WO2012168349A1

  公开（公告）日：2012-12-13

  The present invention relates to compounds of general formula (I), acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmaceutical active ingredients.

  这项发明涉及一般式(I)的化合物，它们既作为肌肉收缩受体拮抗剂，又作为β2肾上腺素受体激动剂，涉及它们的制备方法，包含它们的组合物，治疗用途以及与其他药用活性成分的组合。
• [EN] 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE 3,6-DISUBSTITUES AZABICYCLO HEXANE UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE MUSCARINIQUE
  申请人：RANBAXY LAB LTD

  公开号：WO2004067510A1

  公开（公告）日：2004-08-12

  This invention generally relates to derivatives of 3,6 disubstituted azabicyclo hexanes.The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

  这项发明通常涉及3,6-二取代氮杂环己烷衍生物。本发明的化合物可以作为毒蕈碱受体拮抗剂发挥作用，并可用于治疗通过毒蕈碱受体介导的呼吸道、泌尿道和消化系统的各种疾病。该发明还涉及含有本发明化合物的药物组合物以及治疗通过毒蕈碱受体介导的疾病的方法。
• 3,6-Disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
  申请人：Mehta Anita

  公开号：US20060217432A1

  公开（公告）日：2006-09-28

  The invention relates to derivatives of 3,6-disubstituted azabicyclo[3.1.0]hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

  本发明涉及结构为（I）的3,6-二取代的氮杂双环[3.1.0]己烷衍生物。本发明的化合物可以作为毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。本发明还涉及含有本发明化合物的制药组合物以及治疗通过毒蕈碱受体介导的疾病的方法。
• Process for preparing 3,6-disubstituted azabicyclo derivatives
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2177511A2

  公开（公告）日：2010-04-21

  This invention relates to processes for preparing derivatives of 3,6-disubstituted azabicyclo compounds that can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors.

  本发明涉及制备 3,6-二取代氮杂双环化合物衍生物的工艺，这些衍生物可作为毒蕈碱受体拮抗剂，用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和胃肠道系统的各种疾病。